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and recognition, catalysis, or interaction with other pro-Cytochrome P450
teins and the membrane.Conformational Diversity Cytochrome P450 structures manifest a range of con-
formations. For example, Cyp119 alters the FG loop,
which folds over the active site, in response to different
inhibitors (Poulos, 2003; PDB entries 1F4U, 1F4T, 1IO7),
Cytochrome P450s display a remarkable range of con- and P450 BM-3 undergoes reorganization upon binding
formations in parallel with activity toward a great di- its fatty acid substrate (Haines et al., 2001; 1JPZ). In-
versity of substrates. This aspect of P450s now ex- duced fit conformational change occurs in mammalian
tends to include the dynamic behavior of the protein, P450 2C5 upon binding diclofenac, but an inhibitor binds
as shown by recent crystal structures of Cyp51 (Po- in two orientations without change in the active site
dust et al., 2004b, this issue of Structure). (Wester et al., 2003; 1NR6, 1N6B). Recently, high-resolu-
tion crystal structures of human P450s 2C8, 2C9, and
3A4 have revealed a dimeric state of the enzyme, aP450s are everywhere. A prime example is Cyp51, a
trapped effector molecule, large variation in active siteP450 found in organisms from all kingdoms of life. In this
volume, and rearrangement of the helical elements andissue of Structure, L.M. Podust and colleagues describe
loops surrounding the active site (Yano et al., 2004;crystal structures of Cyp51 in which a key portion of the
1PQ2, 1R9O, 1TQN).enzyme remains disordered upon binding its substrate.
Podust et al. (2004b) describe structures of Cyp51This result expands the scope of conformational diver-
from Mycobacterium tuberculosis as the substrate freesity observed for these remarkable enzymes. At the
enzyme and in complex with the lanosterol analog es-same time, the results provide insight into the challenge
triol. Biosynthesis of cholesterol and steroid hormonesfor drug design targeting this P450 in pathogenic or-
proceeds only via oxidative removal of the 14-methylganisms.
group from the precursor, which is lanosterol in yeastCytochrome P450s catalyze the monooxygenation of
and animals, and requires Cyp51. The estriol complexhydrophobic substrates utilizing a heme cofactor, O2,
permits contact residues to be mapped within the activeand reducing equivalents from auxiliary proteins. The
site and correlated with conserved residues in 59 Cyp51reactions catalyzed are diverse and include aliphatic
sequences from mammals, fish, plants, fungi, and bacte-and aromatic hydroxylations, epoxidations, and dealkyl-
ria. This accounts for the selectivity of Cyp51 towardations. Over 3700 cytochrome P450 genes have been
one of four different steroid substrates. Furthermore,identified in bacteria, plants, fungi and lower eukaryotes,
the structures reveal disorder in the BC loop and C helixand animals; there are 57 genes and 58 pseudogenes
in the absence of substrate. These segments becomein the human genome (Nelson et al., 2004). About one-
ordered upon binding an inhibitor (Podust et al., 2001;
third of mammalian P450s catalyze specific steps in the
1EA1, 1E9X) (Figure 1B), but remain significantly disor-
biosynthesis of steroid hormones, cholesterol, prostan-
dered upon binding the steroidal substrate (Podust et
oids, and bile acids. The remainder are involved in the al., 2004b; 1H5Z, 1X8V). One consequence is that the
catabolism of endogenous compounds, including fatty heme and active site in Cyp51 are exposed for substrate
acids and steroids, and in the degradation of exogenous access from a direction orthogonal to that in other
compounds, including drugs and carcinogens. In con- P450s. These regions of the P450 fold have not been
trast to the biosynthetic P450s, which are highly specific observed to be so extensively disordered until now.
for their substrates, the drug metabolizing enzymes oxi- However, the BC loop and C helix have been observed to
dize chemically diverse compounds and yet display undergo extensive rearrangement in the “open” versus
marked regio- and stereoselectivity. Substrate selectiv- inhibitor bound, “closed” forms of P450 2B4 (Scott et
ity in these P450s influences the efficacy and develop- al., 2004; 1PO5, 1SUO) (Figure 1B). Also, the adjacent B
ment of new drugs. helix is disordered in the open conformations of P450s
A central problem to understanding the function of OxyB and OxyC (Pylypenko et al., 2003; 1LFK, 1UED),
cytochrome P450s is akin to that of antibodies in the and variable in the open forms of Cyp154C1 and
immune system, i.e., activity by a single class of proteins Cyp154A1 (Podust et al., 2004a; 1GWI, 1ODO). Refolding
against a diverse array of ligands with retention of speci- of the B helix is also seen in response to substrate
ficity. At least 20 unique P450 crystal structures have binding in P450 2C9 (Yano et al., 2004; 1R9O) and
been determined, and the PDB contains over 110 P450- P450cin (Poulos, 2003; 1T2B). Hence, conformational
related entries. Cytochrome P450s share an interdig- flexibility in the B helix, BC loop, and C helix allows
itated fold with a -helical bundle that surrounds the separation of the  sheet and -helical domains, to open
heme adjacent to a mixed  sheet (Figure 1A). The active the active site, and is important for induced fit binding
site is on the distal side of the heme, and is defined by of substrate.
the F and I helices, the FG loop, a short helix between Cyp51 is a primary target for antifungal agents, includ-
the B and C helices (denoted B), the BC loop, a  ing the azole inhibitor fluconazole. When mutations that
strand following the K helix, and an antiparallel -loop give rise to azole resistance in the pathogen Candida
near the C terminus. All portions of the molecule contrib- albicans are mapped onto Cyp51, a striking correlation
is observed. The mutated residues correspond to theute in some way to heme coordination, substrate binding
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Figure 1. Conformational Variation in Cyto-
chrome P450 2B4 and Cyp51
(A) Flexible elements of the cytochrome P450
fold are highlighted with respect to the open
conformation of P450 2B4. These portions of
the protein define the direction of access to
the active site and heme. The structure is
colored according to increasing temperature
factor (blue through red). The A, F, G, and I
helices are also indicated.
(B) Comparison of B helix, BC loop, and C
helix in P450s Cyp51 and 2B4. The protein
segments are colored according to increas-
ing temperature factor as in (A). The open
form of 2B4 (orange label; 1PO5) undergoes
a large conformation change upon binding
inhibitor in the closed form (blue label and
Cl-phenylimidazole; 1SUO); this involves re-
folding of the B helix, and significant dis-
placement of the C helix. By comparison, the
inhibitor bound form of Cyp51 (green label
and phenylimidazole; 1E9X) displays a very
different conformation of the BC loop. In the absence substrate, Cyp51 (yellow label; 1H5Z) adopts a similar conformation of the B helix and
part of the BC loop; however, the remainder of the BC loop and most of the C helix are disordered. As shown in this issue of Structure (Podust
et al., 2004b), the BC loop and C helix remain largely disordered even upon binding a steroid substrate.
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